Table 1
Status of small molecule JNK inhibitors in clinical trials
Name
Structure
Company
Most advanced phase/indication
Status (year)
AS602801
GL5001
bentamapimod
CN
N
N
O
N
O
S
N
PregLem SA
Phase II/inflammatory endometriosis
Completed (2013)
a
CC-401
N
H
N
N
N
N
H
O
N
Celgene
corporation
Phase I/refractory acute myelogenous
leukemia
Terminated (2006)
a
CC-930
tanzisertib
HO
H
N
N
N
N
N
NH
F
F
F
O
Celgene
corporation
Phase II/pulmonary
fibrosis
Phase II/discoid lupus
Terminated (2012)
a
Terminated (2016)
a
CC-90001
Undisclosed
Celgene
corporation
Phase II/idiopathic pulmonary
fibrosis
Ongoing/recruiting
(2017)
b
Data were obtained from the webpage https://clinicaltrials.gov (Accessed on October 29, 2018)
a
Study completion date
b
Study start date
Inhibitors of c-Jun N-Terminal Kinase 3
207
Status of small molecule JNK inhibitors in clinical trials
Name
Structure
Company
Most advanced phase/indication
Status (year)
AS602801
GL5001
bentamapimod
CN
N
N
O
N
O
S
N
PregLem SA
Phase II/inflammatory endometriosis
Completed (2013)
a
CC-401
N
H
N
N
N
N
H
O
N
Celgene
corporation
Phase I/refractory acute myelogenous
leukemia
Terminated (2006)
a
CC-930
tanzisertib
HO
H
N
N
N
N
N
NH
F
F
F
O
Celgene
corporation
Phase II/pulmonary
fibrosis
Phase II/discoid lupus
Terminated (2012)
a
Terminated (2016)
a
CC-90001
Undisclosed
Celgene
corporation
Phase II/idiopathic pulmonary
fibrosis
Ongoing/recruiting
(2017)
b
Data were obtained from the webpage https://clinicaltrials.gov (Accessed on October 29, 2018)
a
Study completion date
b
Study start date
Inhibitors of c-Jun N-Terminal Kinase 3
207